NDLI: Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.

Please wait, while we are loading the content...

Current and future directions of pharmacokinetic and pharmacokinetic-pharmacodynamic modelling and simulation: population approach group in Europe 19th annual meeting.

Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion.

Are rats the appropriate experimental model to understand age-related renal drug metabolism and toxicity?

Herb-drug pharmacokinetic interactions reviewed.

Cardiac slices as a predictive tool for arrhythmogenic potential of drugs and chemicals.

Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.

Challenges and solutions to metabolites in safety testing: impact of the International Conference on Harmonization M3(R2) guidance.

Pharmacokinetic evaluation of etravirine.

Pharmacokinetic evaluation of continuous intravenous epoprostenol.

Year: 2010 Volume: 6 Issue: 11

Year: 2010 Volume: 6 Issue: 10

Year: 2010 Volume: 6 Issue: 9

Year: 2010 Volume: 6 Issue: 8

Year: 2010 Volume: 6 Issue: 7

Year: 2010 Volume: 6 Issue: 6

Year: 2010 Volume: 6 Issue: 5

Year: 2010 Volume: 6 Issue: 4

Year: 2010 Volume: 6 Issue: 3

Year: 2010 Volume: 6 Issue: 2

Year: 2010 Volume: 6 Issue: 1

Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Nichols, Alice I. Tourian, Karen A. Tse, Susanna Y. Paul, Jeffrey
Description	Country affiliation: United States Author Affiliation: Nichols AI ( Pfizer, Inc., (formerly Wyeth Research), Collegeville, PA 19426, USA. Alice.Nichols@pfizer.com)
Abstract	IMPORTANCE OF THE FIELD: genetic and pharmacologically-driven variations in common mechanisms involved in the disposition of antidepressant medications may contribute to variable interpatient response. This review describes the pharmacological properties underlying the safety and efficacy of desvenlafaxine, a second-generation serotonin-norepinephrine reuptake inhibitor (SNRI). AREAS COVERED IN THIS REVIEW: literature published between January 2006 and September 2010 evaluating desvenlafaxine was reviewed. WHAT WILL THE READER GAIN: Desvenlafaxine therapy is initiated at the therapeutic dose (50 mg/day) without a need for dose titration. Desvenlafaxine metabolism and distribution are not appreciably affected by altered function of cytochrome P450 (CYP) enzymes or permeability glycoprotein (P-gp). Desvenlafaxine has clinically insignificant effects on the activity of CYP and P-gp. The efficacy of desvenlafaxine in treating major depressive disorder has been established. Adverse events are characteristic of the SNRI class. Notably, the rate of discontinuation due to adverse events with the 50 mg/day recommended therapeutic dose is comparable to that seen with placebo. TAKE HOME MESSAGE: incremental benefits with desvenlafaxine, derived from straight-forward dosing, a simple metabolic profile and lack of interaction with active transporter P-gp and CYP enzymes may contribute to more consistent response, good tolerability and lower incidence of drug-drug interactions with concomitant medications.
File Format	HTM / HTML
ISSN	17425255
Issue Number	12
Volume Number	6
e-ISSN	17447607
Journal	Expert Opinion on Drug Metabolism & Toxicology
Language	English
Publisher	Taylor & Francis
Publisher Date	2010-12-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Analytical Chemistry Discipline Pharmacology Antidepressive Agents Therapeutic Use Cyclohexanols Depressive Disorder, Major Drug Therapy Adrenergic Uptake Inhibitors Adverse Effects Pharmacology Animals Cytochrome P-450 Enzyme System Metabolism Physiopathology Desvenlafaxine Succinate Drug Interactions Humans P-glycoprotein Serotonin Uptake Inhibitors Journal Article Research Support, Non-u.s. Gov't Review
Content Type	Text
Resource Type	Article
Subject	Medicine Toxicology Pharmacology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Desvenlafaxine succinate for the treatment of major depressive disorder.

Desvenlafaxine for the treatment of major depressive disorder.

Desvenlafaxine: another 'me too' drug?

Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms.

Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.

Antidepressant drug development: Focus on triple monoamine reuptake inhibition.

Desvenlafaxine in the treatment of major depressive disorder.

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.

Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.

Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.

Similar Documents

Desvenlafaxine succinate for the treatment of major depressive disorder.

Desvenlafaxine for the treatment of major depressive disorder.

Desvenlafaxine: another 'me too' drug?

Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms.

Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence.

Antidepressant drug development: Focus on triple monoamine reuptake inhibition.

Desvenlafaxine in the treatment of major depressive disorder.

A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.

Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.

Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor.